Prevention of Postpartum Hemorrhage With TXA

Exclusion Criteria

• •Age less than 18 years
• •Unable to speak or understand English
• •Not planning to deliver at NMCSD
• •Planned cesarean hysterectomy
• •Current anticoagulant use
• •Current subarachnoid hemorrhage
• •Any active/current intravascular clotting (i.e. venous thromboembolic events)
• •Patients with a hypersensitivity to TXA or any of the ingredients
• •Personal history of venous or arterial thrombotic events
• •Conditions that predispose patients to thromboembolic events (e.g. thrombophilias, autoimmune diseases such as lupus, active cancer, congestive heart failure, family history of thrombosis in a first degree relative at age \< 30 years) due to increased risk of thrombosis
• •Patients taking factor IX complex concentrates or anti-inhibitor coagulant concentrates (e.g. FEIBA NF)
• •Eclampsia or seizure disorder because the use of tranexamic acid has been associated with postoperative seizures
• •Patients with a baseline creatinine 1.2 or higher, history of renal insufficiency, or renal disease because of the risk of toxicity in patients with preexisting disease
• •Patients with frank hematuria because ureteral obstruction due to clot formation has been reported in patients with upper urinary tract bleeding who were treated with tranexamic acid
• •Patients with active or history of retinal diseases as cases of central retinal artery and central retinal vein obstruction have been reported in patients treated with intravenous tranexamic acid
• •Patients with acquired defective color vision